GynEC^{®}-DX is an early diagnosis test exclusively aimed at health professionals, gynecologists or pathologists, who want to rule out cancer in patients at risk.

# FAQs for laboratories

The **reliability **or accuracy of a diagnostic test is the probability that a correct result is obtained. It is calculated by dividing the sum of true positives and true negatives by the total of samples. The clinical study demonstrated that GynEC^{®}-DX has a reliability of **96.5%**.

The **specificity** of a test is the probability that a healthy subject will have a negative test result. The clinical study showed that GynEC^{®}-DX has a specificity of **97%**.

The sensitivity is the probability of correctly classifying a sick individual, ie the probability that a positive result will be obtained for a sick person. The clinical study showed that GynEC^{®}-DX has a sensitivity of** 91%**.

It is the probability of not having the disease if the result of the diagnostic test is negative. The clinical study showed that GynEC^{®}-DX has a **NPV** of **99%**.

It is the probability of having the disease if the result of the diagnostic test is positive. The clinical study showed that GynEC^{®}-DX has a **PPV** of **79%**.

The calculation of these values is explained in the following pages:

In the development phase, 20 genes biomarkers of early stages of endometrial cancer were identified (Int. J. Cancer 2011, 129: 2435–44): ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 y DCN

The mean duration of endometrial cancer development is unknown, furthermore this time depends on factors such as age, obesity, previous treatment with hormones, family history, etc. It is the physician who, depending on the patient’s clinical history and symptoms, adjusts the follow-up.